BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

  • About
    • Overview
    • Management Team
    • Board of Directors
    • Strategic Advisors
  • Product Pipeline
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Publications
    • Events
    • Media
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
    • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Business Development
  • Careers
    • Overview
    • Job Openings
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • IR Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Press Coverage
  • IR Calendar
  • Email Alerts

BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 14, 2020

BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast

Aug 7, 2020

BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference

Aug 6, 2020

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

Jul 28, 2020

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

Jul 27, 2020

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

Jul 20, 2020

BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation

Jul 9, 2020

BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation

Jul 7, 2020

BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer

Jun 23, 2020

BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer

Jun 16, 2020
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...15
    © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap